September 10, 2021
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
| Attention: | Dillon Hagius |
Chris Edwards
Kristin Lochhead
Terence O’Brien
| Re: | Tyra Biosciences, Inc. |
Registration Statement on Form S-1 (File No. 333-258970)
Request for Acceleration of Effective Date
Dear Ladies and Gentlemen:
In connection with the proposed offering of the securities under the above-captioned Registration Statement on Form S-1 (the “Registration Statement”), we wish to advise you that we, as representatives of the underwriters, hereby join with Tyra Biosciences, Inc.’s request that the effective date of the Registration Statement be accelerated so that the same will become effective on September 14, 2021 at 4:00 p.m. Eastern Time, or as soon as practicable thereafter.
Pursuant to Rule 460 under the Securities Act of 1933, please be advised that, as representatives of the underwriters, we have distributed approximately 976 copies of the preliminary prospectus, dated September 9, 2021, through the date hereof.
We, the undersigned, as representatives of the several underwriters, will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
[Signature Page Follows]
| Sincerely,
BOFA SECURITIES, INC. JEFFERIES LLC COWEN AND COMPANY, LLC
As representatives of the Underwriters
BOFA SECURITIES, INC. | ||
| By: | /s/ Michael Liloia | |
| Name: Michael Liloia | ||
| Title: Director | ||
| JEFFERIES LLC | ||
| By: | /s/ Michael Brinkman | |
| Name: Michael Brinkman | ||
| Title: Managing Director | ||
| COWEN AND COMPANY, LLC | ||
| By: | /s/ Bill Follis | |
| Name: Bill Follis | ||
| Title: Managing Director | ||
[Signature Page to UW Acceleration Request]